title: mu-Opioid receptor modulates peptide release from rat neurohypophysial terminals by inhibiting Ca(2+) influx.
abstract: The activation of opioid receptors in neurones of the central nervous system leads to a variety of effects including the modulation of diuresis and parturition, processes that are directly controlled by the hypothalamic-neurohypophysial system (HNS). The effects of mu-opioid receptor activation on peptide release, voltage-gated Ca2+ currents and intracellular calcium levels ([Ca2+]i) were studied in isolated nerve terminals of the HNS. The mu-receptor agonist, DAMGO ([d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin) inhibited high K+-induced peptide release in a dose-dependent manner, with oxytocin release being more sensitive to block than vasopressin release at all concentrations tested. The addition of the mu-receptor antagonist CTOP (d-Phe-Cys-Tyr-d-Trp-Orn-Thr-Pen-Thr amide) was able to overcome the inhibitory effects of DAMGO. By contrast to previous results, voltage-gated Ca2+ currents were sensitive to blockage by DAMGO and this inhibition was also prevented by CTOP. Furthermore, [Ca2+]i measurements with Fura-2 corroborated the inhibition by DAMGO of calcium entry and its reversal by the micro -receptor antagonist in these nerve terminals. Thus, the decrease in neuropeptide release, particularly for oxytocin, induced by the activation of mu-opioid receptors in neurohypophysial terminals is mediated, at least in part, by a corresponding decrease in Ca2+ entry due to the inhibition of voltage-gated Ca2+ channels.
authors.affiliation: Department of Physiology and Program in Neuroscience and Neurobiology, University of Massachusetts Medical School, Worcester, MA, USA.
authors.forename: S I
authors.initials: SI
authors.lastname: Ortiz-Miranda
authors.forename: G
authors.initials: G
authors.lastname: Dayanithi
authors.forename: V
authors.initials: V
authors.lastname: Coccia
authors.forename: E E
authors.initials: EE
authors.lastname: Custer
authors.forename: S
authors.initials: S
authors.lastname: Alphandery
authors.forename: E
authors.initials: E
authors.lastname: Mazuc
authors.forename: S
authors.initials: S
authors.lastname: Treistman
authors.forename: J R
authors.initials: JR
authors.lastname: Lemos
mesh_terms: D000818:Animals; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D015220:Calcium Channels / Q000187:drug effects / Q000502:physiology; D004553:Electric Conductivity; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000494:pharmacology; D007425:Intracellular Membranes / Q000378:metabolism; D008297:Male; D009411:Nerve Endings / Q000378:metabolism*; D009479:Neuropeptides / Q000378:metabolism*; D009994:Osmolar Concentration; D010904:Pituitary Gland, Posterior / Q000378:metabolism*; D051381:Rats; D017450:Receptors, Opioid, mu / Q000502:physiology*
chemical_list: D002121:Calcium Channel Blockers; D015220:Calcium Channels; D009479:Neuropeptides; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D002118:Calcium